Acceleron Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acceleron Pharma generated cash of -$130,327,000, which is less than the previous year. Cash used in financing activities reached the amount of $538,006,000 last year. Net change in cash is therefore $433,275,000.
Cash Flow
| 2011 | 9.05M | -27K | 21.09M |
|---|---|---|---|
| 2012 | -38.88M | -441K | 13.89M |
| 2013 | -19.65M | -307K | 93.50M |
| 2014 | -53.22M | -514K | 117.03M |
| 2015 | -44.21M | -108.97M | 4.50M |
| 2016 | -44.69M | -108.80M | 146.66M |
| 2017 | -76.73M | -64.36M | 220.29M |
| 2018 | -94.70M | 122.92M | 16.14M |
| 2019 | -93.80M | -71.29M | 258.72M |
| 2020 | -130.32M | 25.59M | 538.00M |
XLRN Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 239.27M | 145.64M | 101.28M | 20.95M | 27.78M | 176.46M | 113.16M | 39.61M | 65.03M | 34.91M |
Operating activities | ||||||||||
Net income | -166.03M | -124.85M | -118.87M | -108.45M | -57.01M | -63.89M | -51.25M | -21.89M | -32.58M | 36.26M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.84M | 3.94M | 3.74M | 2.82M | 1.67M | 1.17M | 1.11M | 915K | 1.29M | 3.13M |
Stock-based compensation expense | 30.23M | 22.99M | 24.56M | 28.24M | 18.55M | 12.07M | 4.77M | 2.19M | 1.20M | 1.42M |
| Deferred income tax benefit | 30.23M | 22.99M | 24.56M | 28.24M | 18.55M | 12.07M | 4.77M | 2.19M | 1.20M | 1.42M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -17.55M | -1.50M | -3.47M | -336K | 394K | -261K | 249K | -840K | -1.11M | 1.83M |
Inventories | -404.81M | -287.46M | -264.35M | -129.79M | -97.48M | -172.94M | -91.9M | -4.16M | 0 | 0 |
Accounts payable | 5.83M | 1.87M | -673K | -504K | 644K | 151K | -161K | -53K | -1.27M | 334K |
Cash generated by operating activities | -130.32M | -93.80M | -94.70M | -76.73M | -44.69M | -44.21M | -53.22M | -19.65M | -38.88M | 9.05M |
Investing activities | ||||||||||
Purchases Of Investments | -238.22M | -395.13M | -73.57M | -179.93M | -218.31M | -134.69M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.20M | -3.28M | -2.59M | -4.39M | -3.38M | -959K | -514K | -307K | -441K | -27K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 25.59M | -71.29M | 122.92M | -64.36M | -108.80M | -108.97M | -514K | -307K | -441K | -27K |
Financing activities | ||||||||||
Common Stock Issued | 492.41M | 248.13M | 0 | 215.80M | 140.69M | 542K | 129.17M | 96.82M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -47K | 0 | -300K | 0 | 0 |
Repayments of term debt | 0 | 0 | -139K | 0 | 0 | 0 | -16.33M | -3.66M | -6.19M | -9.47M |
Cash used in financing activities | 538.00M | 258.72M | 16.14M | 220.29M | 146.66M | 4.50M | 117.03M | 93.50M | 13.89M | 21.09M |
Net Change In Cash | 433.27M | 93.62M | 44.36M | 79.2M | -6.83M | -148.67M | 63.29M | 73.55M | -25.42M | 30.12M |
Cash at end of period | 672.54M | 239.27M | 145.64M | 100.15M | 20.95M | 27.78M | 176.46M | 113.16M | 39.61M | 65.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |